New Crown Vaccine | Xu Shuchang said that the introduction of the third phase of the report belongs to the WHO standard, Singapore is also waiting for Kexing

Social News

Author: Zhu Haiqi

2021-01-28 16:44

Last update date: 2021-01-28 16:44

The Hong Kong government has ordered one of the mainland Kexing vaccines and has not yet announced the third phase clinical report. Some people have suggested another Sinopharm vaccine that has been vaccinated in the mainland, but the third phase report of the Sinopharm vaccine has not been released.

Some experts have pointed out that the introduction of vaccines in the third report is the World Health Organization standard. In fact, Singapore and Hong Kong are waiting for the third report of Kexing; some experts explained that the introduction of vaccines is a major public health decision. Regulators have the responsibility to obtain information and data from pharmaceutical companies before purchasing to protect public safety. Otherwise, it may constitute public officials' misbehavior. "It is a potential health problem of a group of individuals. Important decisions must be made. Public officials must exercise caution."

▼Vaccination experts answer nine questions▼

+3

+3

+3

Singapore also waited for the Kexing report before considering whether to introduce a member of the

Government’s Vaccine Advisory Expert Committee and Chair Professor of Respiratory Department of CUHK, Xu Shuchang pointed out that the vaccine must be used in the third phase of the clinical report, which is the standard of developed regions and the World Health Organization. The third report of Pfizer/BioNTech and Modena vaccines used in Europe and the United States is published in "Needle" and "New England Journal of Medicine". Singapore has ordered the Coxing vaccine like Hong Kong, but the local area is waiting for Coxing's release. The third-phase report was considered for introduction.

Xu Shuchang pointed out that it is the WHO standard to introduce only vaccines with the third report.

(Data Picture / Photo by Yu Junliang)

The third phase of the report can detail vaccine safety, effectiveness, side effects, time of onset, etc.

Respiratory system specialist Liang Zichao said that whether the vaccine is introduced into Hong Kong or not depends on whether the pharmaceutical company provides the data of the third phase of the report to local health institutions. Because the report can learn in detail about the vaccine’s safety, effectiveness, side effects, time of onset, and age of the onset group, if the information provided by the pharmaceutical company at the press conference is not comprehensive, experts cannot judge the reliability of the vaccine.

He believes that after the pharmaceutical company submits the data to the Hong Kong Department of Health, even if the third issue of the report is not published in an authoritative medical journal, there is no problem, "Is it necessary to use the journal? All errors can be made." On the contrary, the Department of Health and experts are more responsible. Review the information according to local conditions, because vaccination is a major public health incident. If the approval process is not rigorous, it can cause public officials to misbehave. "It is a potential health problem of a group of individuals. Important decisions should be made. Public officials must be careful to implement them. "

Liang Zichao said that the third report has detailed data for experts to analyze the effectiveness and safety of the vaccine.

(Profile picture)

Sinopharm's vaccine has been injected in the Mainland and whether it is safe and effective cannot be compared.

Sinopharm's vaccine has been injected with more than 10 million injections in the Mainland. Can it be proved that the Sinopharm vaccine is safe and effective?

Liang Zichao pointed out that there may be differences in the groups of vaccinations in the two places, and pharmaceutical companies still need to submit data for experts to consider. Although Hong Kong used to "give the green light" with reference to other countries when introducing drugs, there are multiple studies and the development time is short. In 10 years, two countries will introduce drugs after they have been used, and the new crown pneumonia vaccine has only been available for a few months. Each place should be considered independently according to its own epidemic situation.

New Crown Vaccine | HKU Research indicates that only 46% of citizens are interested in getting an injection, plummeting 18% within two months

German media claims that the AstraZeneca vaccine is only 8% effective for the elderly

Kexing Sinopharm | Tang Jiahua does not agree to wait for the report Kong Fanyi: It is better to abandon the advisory committee without a report

New crown vaccine | Kong Fanyi: 4 weeks after vaccination, the most important thing is to emphasize that vaccine safety is the most important

01News

New crown pneumonia new crown vaccine